SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences this month:
- 16th UC San Diego Moores Cancer Center Industry/Academia "Next Generation Precision Oncology" Symposium: Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will speak during a session devoted to solid tumors. The presentation will take place at 9:15 a.m. PST on Thursday, February 20, 2020 in La Jolla, California.
- 9th Annual SVB Leerink Global Healthcare Conference: Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will provide a company overview at 2:00 p.m. EST on Tuesday, February 25, 2020 in New York, New York.
- Biocom’s Annual Global Life Sciences Partnering Conference: Scott Moorefield, Ph.D., Chief Business Officer of Boundless Bio, will present a company overview at 11:45 a.m. PST on Wednesday, February 26, 2020 in La Jolla, California.
Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells’ chromosomes and can make many copies of themselves. ecDNA can be rapidly replicated within the cell, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division. Cells have the ability to upregulate or downregulate ecDNA and resulting oncogenes to ensure survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment evasion. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
About Boundless Bio
Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com.